CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Invitrocue Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Invitrocue Ltd
L 2 350 Kent St
Phone: +61 292992289p:+61 292992289 Sydney, NSW  2000  Australia Fax: +61 292992239f:+61 292992239

This company is no longer actively traded on any major stock exchange.

Business Summary
Invitrocue Limited is engaged in research and experimental development on biotechnology, life and medical science. The Company offers a three dimension (3D) cell-based scaffolding technology, which mimics a human for Tropical Diseases to investigate the lifecycle of Plasmodium cynomolgi (monkey malaria) and helps in evaluating new drug targets to malaria infection using in vitro hepatocyte culture systems. It is engaged in developing non-small cell lung cancer organoids and for drug testing programs using approved drugs. It is also engaged in range of activities, including in vitro cell-based assays, patient-derived organoids, digital pathology and medical imaging, while providing access to industry networks. It also offers an in vitro screening of experimental drug compounds for anti-leishmanial activity. It intends to develop an in vitro 3D perfused liver model to expedite and facilitate new application notes in infectious liver diseases.
(Source: ARS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20196/30/2019Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Boon SingFang 1/9/2019 1/15/2016
Senior Vice President - Scientific Affairs and Corporate Development SunnyTan 9/28/2017 9/28/2017
Company Secretary, Director Chow YeeKoh 3/2/2020 5/18/2015
Non-Executive Director AntonyEaton 9/18/2019 9/18/2019
Non-Executive Director AndreasLindner 2/6/2018 2/6/2018

Business Names
Business Name
Ellect Holdings Limited
Intellect Holdings Limited
IVQ

General Information
Number of Employees: 83 (As of 6/30/2005)
Outstanding Shares: 525,325,685 (As of 6/30/2019)
Shareholders: 3,688
Stock Exchange: ASX
Fax Number: +61 292992239


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023